Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 9617 - 9624 of 12086 results

Spring Spotlight on Food Labeling, Safety & Nutrition
April 9, 2015| Blog| Viewpoint

CMS Takes Initial Steps to Address Medicare & Medicaid Coverage for Biosimilars
April 9, 2015| Blog| Viewpoint

ECO:nomics 2015 - Top 10 Takeaways
April 8, 2015| Blog| Viewpoint

Preserving Net Operating Losses (NOL) Carryforward: What Are You Doing to Protect Your Company’s Valuable Tax Assets?
April 8, 2015| Blog| Viewpoint

Massachusetts Announces Significant Changes to the Medical Marijuana Dispensary Program
April 8, 2015| Blog| Viewpoint

2015 Employment Law Issues Tournament: The Championship (and the First-Ever Rendition of "One Shining Lawsuit")
April 7, 2015| Blog| Viewpoint

H-1B Cap Hit for Fiscal Year 2016
April 7, 2015| Alert| Viewpoint

Video Interview: Discussing Cross-Device Tracking on LXBN TV
April 7, 2015| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
